Kairos Pharma has received the 2026 Biotech Breakthrough Award for its cancer treatment ENV-105.

Nov 7, 2026, 9:19 AM ETMarketRead the original at tradingview.com

Good for KAPA

Kairos won an award for ENV-105, and an earlier study found the drug combination delayed cancer worsening versus apalutamide alone. ENV-105 is still being tested, but that study result makes the news positive for Kairos.

KAPA · Kairos Pharma

AI read · Good for KAPA

The AI's read

The award may bring attention to Kairos's cancer treatment. An earlier study found a significant benefit in how long patients went before their cancer worsened. ENV-105 is still being tested, so these results do not show it will help all patients or become an approved treatment.

Get alerts for KAPA

Follow Kairos Pharma (KAPA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KAPA

Free on the App Store and Google Play, or on the web.